|
Apr 1
|
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
|
|
Jan 18
|
OTC Markets Group Announces the 2024 OTCQX Best 50
|
|
Dec 29
|
Antibe Announces Early Warrant Exercise Incentive Program
|
|
Nov 13
|
Antibe Reports Q2 2024 Interim Financial and Operating Results
|
|
Nov 9
|
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
|
|
Nov 1
|
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
|
|
Sep 8
|
Antibe Announces Results of 2023 Annual Meeting
|